Article Sidebar

pdf
Date Published: 24/11/2023
Abstract Views: 108
Views pdf: 80
DOI: https://doi.org/10.51298/vmj.v532i1.7247
Issue
Vol. 532 No. 1 (2023)
Section
Các bài báo
How to Cite
Đỗ, A. T., & Dương, T. L. (2023). RESULTS OF PROXIMAL TREATMENT OF PATIENTS WITH ORCHIECTOMY - RESISTANT PROSTATE CANCER ACCORDING TO THE DOCETAXEL - PREDNISOLONE REGIMEN. Vietnam Medical Journal, 532(1). https://doi.org/10.51298/vmj.v532i1.7247

RESULTS OF PROXIMAL TREATMENT OF PATIENTS WITH ORCHIECTOMY - RESISTANT PROSTATE CANCER ACCORDING TO THE DOCETAXEL - PREDNISOLONE REGIMEN

Anh Tú Đỗ1,, Thị Lệ Dương2
1 K hospital
2 HMU

Main Article Content

Abstract

Background: Combination of Docetaxel and Prednisone significantly prolongs overall survival. At the same time, the serum PSA response rate was also significantly higher. Purpose: To assess the outcomes of proximal treatment of patients with orchiectomy-resistant prostate cancer with the Docetaxel-Prednisolone regimen at K Hospital. Methods: Cross-sectional analysis of the results of close chemotherapy treatment of 38 patients with CRPC. Results: After 3 chemotherapy cycles, the objective response rate to treatment reached 24%, the disease control rate was 92%. PSA response rate was 53,6%. Median PSA progression-free survival was 6,0 months. The percentage of patients with pain relief was 66,7%. Conclusion: The results of Docetaxel-Prednisolone combined treatment were achieved an objective response rate of 24%, a disease control rate of 92%.

Article Details

Keywords

Prostatic cancer, Proximal outcome, orchiectomy-resistance.

References

1. H. I. Scher, et al., Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol, 2016. 34(12): p. 1402-18.
2. Dawson N. A., Overview of the treatment of disseminated prostate cancer. Available at: uptodate.com.
3. Y. C. Shen, et al., Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer. Kaohsiung J Med Sci, 2016. 32(9): p. 458-63.
4. I. F. Tannock, et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004. 351(15): p. 1502-12.
5. S. Naito, et al., Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol, 2008. 38(5): p. 365-72.
6. G. Song, et al., Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice. Prostate Int, 2013. 1(3): p. 125-32.
7. J. L. Lee, et al., Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat, 2010. 42(1): p. 12-7.
8. J. Y. Joung, et al., Docetaxel chemotherapy of Korean patients with hormone- refractory prostate cancer:comparative analysis between 1st-line and 2nd-line docetaxel. Yonsei Med J, 2008. 49(5): p. 775-82.
9. D. R. Berthold, et al., Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res, 2008. 14(9): p. 2763-7.